Clinical Trial Update: Evaluating in Vivo PARP-1 Expression With 18F-FluorThanatrace Positron Emission Tomography (PET/CT) in Prostate Cancer [EARLY_Phase 1]

View source ↗

Summary

A Phase 1 study evaluating in vivo PARP-1 expression using 18F-FluorThanatrace PET/CT in prostate cancer; currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• 18F-FluorThanatrace

Snippet

Sponsor: Abramson Cancer Center at Penn Medicine | Conditions: Prostate Cancer | EARLY_Phase 1 | Status: ACTIVE_NOT_RECRUITING